Ridinilazole

Synonym(s): SMT 19969

Class: DNA minor groove binder

Spectrum of activity:	Gram-positive
Details of activity:	Binds with AT sequence specificity to the minor groove of DNA and inhibits energy metabolism. Used for C. difficile infection
Institute where first reported:	Summit Corp, UK
Year first mentioned:	2011
Highest developmental phase:	Phase 3
Development status:	Active

Chemical structure(s):
Canonical SMILES:	C1=CC2=C(C=C1C3=CC4=C(C=C3)N=C(C5=CC=NC=C5)N4)NC(=N2)C6=CC=NC=C6
Isomeric SMILES:	C1=CC2=C(C=C1C3=CC4=C(C=C3)N=C(N4)C5=CC=NC=C5)NC(=N2)C6=CC=NC=C6
InChI:	InChI=1S/C24H16N6/c1-3-19-21(29-23(27-19)15-5-9-25-10-6-15)13-17(1)18-2-4-20-22(14-18)30-24(28-20)16-7-11-26-12-8-16/h1-14H,(H,27,29)(H,28,30)
InChI Key:	UHQFBTAJFNVZIV-UHFFFAOYSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/16659285

External links:
Guide to Pharmacology:	ridinilazole
Main Source:	https://www.summittxinc.com/app/uploads/2021/07/ECCMID-2021-Summit-Therapeutics-Ridinilazole-MoA.pdf
Citations:	http://aac.asm.org/content/57/10/4872.full https://www.escmid.org/escmid_publications/escmid_elibrary/?q=SMT+19969&id=2173&L=0&x=26&y=26 http://uhra.herts.ac.uk/handle/2299/14738